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Abstract
We report the first case of early-onset systemic neonatal infection
associated with Moraxella osloensis bacteriemia in a full term baby. The
genus Moraxella is constituted by a group of pleomorphic bacteria
obligate aerobes, Gram-negative, oxidase positive and indole negative
infrequently isolated from clinical specimens. The organism is rarely
reported in the literature as the causative agent of infection in humans,
mostly in immunocompromised patients. Only 12 cases of M. osloensis-
related infections during childhood have been reported in the literature
so far. This unique report of M. osloensis infection, during the neonatal
period, concerns the isolation of the bacteria in purulent secretions from
the eyes of a 3-week-old baby with opthalmia. In our patient, the
precocity of the onset of symptoms allows us to hypothesize a vertical
transmission of the bacteria.
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Introduction
The genus Moraxella is constituted by a group of pleomorphic bacteria
obligate aerobes, Gram-negative, oxidase positive and indole negative,
infrequently isolated from clinical specimens: the main species (M.
catarrhalis, M. nonliquefaciens, M. and M. lincolnii osloensis) colonize as
saprophytes the upper respiratory tract and occasionally the skin and
urogenital tract in humans. (1-3) The clinical significance of M.osloensis
isolates may be difficult to determine, because the organism is rarely
reported in the literature as the causative agent of infection in humans,
mostly immunocompromised patients. (4) We report the first case of
early-onset systemic neonatal infection, most likely due to vertical
transmission of M. osloensis.
Case report
The patient is a Caucasian male born vaginally at 39 weeks gestational
age. The mother had no history of premature rupture of membranes.
Maternal swabs of the lower vagina and rectum had not been performed
during pregnancy; incomplete intrapartum prophylaxis against group B
streptococcus infection was administered (Ampicillin 2 g intravenously,
only the first dose). There was no other obstetric or family history of
interest except for a 3-year-old brother who had received empirical
intravenous antibiotic treatment in the first few days of life (no clinical
data available).
The neonate’s weight, length, and cranial circumference at birth were
4330 g (LGA, large for gestational age), 53.6 cm (LGA) and 34.8 cm
(AGA, adequate for gestational age). APGARs were 9 and10, at 1 and 5
minutes, respectively. At the first neonatal physical examination, no
congenital malformations were detected.
One hour after birth the patient developed bradycardia (frequency rate
90 bpm) and respiratory distress requiring oxygen therapy; lung and
cardiac auscultation were normal; no significant findings of other organs
were detected on examination.
Laboratory workup revealed an increased C-reactive protein (0.032 g/l;
reference values < 0.005 g/l); full blood count showed a normal white
blood cell count and normal values for hemoglobin and platelets;
urinalysis was negative.
Following blood culture, on a single sample (with enriched broth), the
patient was given empiric intravenous antibiotic treatment with
ampicillin+sulbactam. On the second day, blood tests revealed a further
rise of C-reactive protein (0.05 g/l).
During the following days, blood biochemistry showed a progressive
reduction of inflammatory markers and a gradual improvement of the
baby’s clinical condition was observed.
The newborn was discharged from hospital in good clinical condition ten
days later, after completing antibiotic treatment.
On the fifth day after collection, the blood culture came back positive; the
day after, subculture plates (blood agar and chocolate agar) showed a
Gram negative coccobacillus usually not found on the plate for Gram-
negative bacteria (MacConkey agar). At first biochemical identification
(instrumental Phoenix Becton Dickinson and manual Biomerieux API
NH), a bacteria belonging to the genus Moraxella was isolated. To obtain
a definitive identification of the species of the organism, 16S rRNA gene
sequencing was performed and the blood isolate in the present case was
confirmed to be M. osloensis. Our patient’s M. osloensis isolate was
susceptible to ampicillin+sulbactam.
Discussion
Moraxella osloensis is rarely reported in the literature as the causative
agent of infection in humans. The current medical literature on Moraxella
osloensis essentially comes from case reports of infections in humans
(osteomyelitis, meningitis, pneumonia, bacteriemia), in
immunocompromised patients with malignancies. (4-7)
Regarding isolation of the bacteria in the pediatric population, only 12
cases of M. osloensis-related infections in patients aged 0 to 15 years have
been reported in the literature so far. (7-10) Among them, underlying
conditions (complement C8 β deficiency and cerebrospinal fluid shunt)
were present only in two children who both developed meningitis; in the
ten remaining pediatric patients the medical history was unremarkable.
The most recent cases of M. osloensis concerned a 6- year-old Indian boy
with diarrhea and hemolytic uremic syndrome (8) and a 12-year-old
Spanish girl with pyomyositis. (9)
We report the first case of early-onset systemic neonatal infection with
M. osloensis in a full term baby. To our best knowledge, no neonatal M.
osloensis bacteriemias have been described up until now. This unique
report of M. osloensis infection during the neonatal period concerns the
isolation of the bacteria from purulent eye secretions in a 3-week-old
baby with opthalmia. (10) In our patient, the precocity of the onset of
symptoms (only one hour after birth) allows us to hypothesize a vertical
transmission of the bacteria.
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